These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 20678677

  • 1. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.
    JAMA; 2000 Sep 13; 284(10):1247-55. PubMed ID: 10979111
    [Abstract] [Full Text] [Related]

  • 4. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 13; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D, Hughes K, Harris S, Shakir SA.
    Rheumatology (Oxford); 2003 Nov 13; 42(11):1332-41. PubMed ID: 12810929
    [Abstract] [Full Text] [Related]

  • 6. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov 13; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 7. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.
    Cochrane Database Syst Rev; 2014 Oct 23; 2014(10):CD007744. PubMed ID: 25340915
    [Abstract] [Full Text] [Related]

  • 8. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
    Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS.
    Liver Int; 2012 May 23; 32(5):859-66. PubMed ID: 22226322
    [Abstract] [Full Text] [Related]

  • 9. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.
    Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS.
    Pharmacoepidemiol Drug Saf; 2011 Jul 23; 20(7):763-71. PubMed ID: 21618340
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 23; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 11. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 23; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP.
    Aliment Pharmacol Ther; 2010 Nov 23; 32(10):1240-8. PubMed ID: 20955443
    [Abstract] [Full Text] [Related]

  • 13. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.
    Rheumatology (Oxford); 2003 Nov 23; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [Abstract] [Full Text] [Related]

  • 14. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Yuan Y, Hunt RH.
    Curr Pharm Des; 2007 Nov 23; 13(22):2237-47. PubMed ID: 17691997
    [Abstract] [Full Text] [Related]

  • 15. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 16. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.
    Drug Saf; 2005 Feb 10; 28(9):803-16. PubMed ID: 16119973
    [Abstract] [Full Text] [Related]

  • 17. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D, Wilton LV, Shakir SA.
    Eur J Clin Pharmacol; 2004 Sep 10; 60(7):489-501. PubMed ID: 15278327
    [Abstract] [Full Text] [Related]

  • 18. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 Mar 10; 29(3):467-73. PubMed ID: 11908558
    [Abstract] [Full Text] [Related]

  • 19. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LT.
    Arthritis Care Res (Hoboken); 2015 Aug 10; 67(8):1137-49. PubMed ID: 25623277
    [Abstract] [Full Text] [Related]

  • 20. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY, Tsai YW, Huang WF.
    Clin Ther; 2009 Nov 10; 31(11):2618-27. PubMed ID: 20110006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.